Want to see IN:SAILIFE full AI Analyst Report?
SAILIFE Stock Chart & Stats
₹1010.25
₹4.05(0.56%)
At close: 4:00 PM EST
₹1010.25
₹4.05(0.56%)
Day’s Range― - ―
52-Week Range₹779.45 - ₹1,350.90
Previous CloseN/A
Volume67.81K
Average Volume (3M)11.95K
Market Cap
₹279.39B
Enterprise Value₹259.18B
Total Cash (Recent Filing)₹1.58B
Total Debt (Recent Filing)₹2.88B
Price to Earnings (P/E)79.2
Beta1.12
Next Earnings
Aug 06, 2026EPS Estimate
3.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)13.71
Shares Outstanding212,285,660
10 Day Avg. Volume10,862
30 Day Avg. Volume11,945
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)8.20
Price to Sales (P/S)9.29
P/FCF Ratio-282.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,270.00Price Target Upside25.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)18.99
Revenue Forecast (FY)₹26.18B
Bulls Say, Bears Say
Bulls Say
Sharp Revenue And Margin ImprovementSustained double‑digit revenue growth and rising net/EBITDA margins reflect scalable service demand and improved operating leverage in CRDMO work. This durable improvement indicates stronger project throughput, pricing execution and structural profitability across discovery-to-manufacturing services.
Conservative Balance Sheet And Improving ReturnsLow leverage and rising equity/ROE provide strategic flexibility to fund capacity, absorb cycle volatility, and pursue customer programs without heavy refinancing. These balance sheet characteristics support long-term investment in specialized assets and global customer servicing.
Integrated CRDMO Business ModelAn end-to-end CRDMO model lets the company capture value across discovery, process R&D and manufacturing, fostering multi-stage program stickiness. That structural positioning promotes recurring multi-year revenue per program and cross-selling, durable competitive advantage in outsourced pharma services.
Bears Say
Persistent Negative Free Cash FlowDespite stronger operating cash, recurring negative free cash flow shows reinvestment or working-capital absorption is outpacing cash generation. Over months this can force external financing, slow capacity additions or constrain margins if capex and WC demands remain elevated relative to EBITDA.
Gross Margin PressureA decline in gross margin points to input-cost or pricing squeeze at the core manufacturing level. If structural, this erodes the profit pool available to cover fixed costs and capex, making sustaining current operating margins and funding expansion harder without price recovery or cost reductions.
Revenue Dependent On Program ProgressionRevenue durability relies on molecules advancing through customer pipelines; program terminations or slower advancement can materially reduce multi-year revenue. This structural dependence on client R&D outcomes increases revenue volatility and makes backlog conversion a key ongoing risk.
SAI Life Sciences Ltd. News
SAILIFE FAQ
What was SAI Life Sciences Ltd.’s price range in the past 12 months?
SAI Life Sciences Ltd. lowest stock price was ₹779.45 and its highest was ₹1350.90 in the past 12 months.
What is SAI Life Sciences Ltd.’s market cap?
SAI Life Sciences Ltd.’s market cap is ₹279.39B.
When is SAI Life Sciences Ltd.’s upcoming earnings report date?
SAI Life Sciences Ltd.’s upcoming earnings report date is Aug 06, 2026 which is tomorrow.
How were SAI Life Sciences Ltd.’s earnings last quarter?
SAI Life Sciences Ltd. released its earnings results on May 14, 2026. The company reported ₹4.9 earnings per share for the quarter, missing the consensus estimate of ₹5.1 by -₹0.2.
Is SAI Life Sciences Ltd. overvalued?
According to Wall Street analysts SAI Life Sciences Ltd.’s price is currently Undervalued.
Does SAI Life Sciences Ltd. pay dividends?
SAI Life Sciences Ltd. does not currently pay dividends.
What is SAI Life Sciences Ltd.’s EPS estimate?
SAI Life Sciences Ltd.’s EPS estimate is 3.6.
How many shares outstanding does SAI Life Sciences Ltd. have?
SAI Life Sciences Ltd. has 212,285,660 shares outstanding.
What happened to SAI Life Sciences Ltd.’s price movement after its last earnings report?
SAI Life Sciences Ltd. reported an EPS of ₹4.9 in its last earnings report, missing expectations of ₹5.1. Following the earnings report the stock price went up 2.42%.
Which hedge fund is a major shareholder of SAI Life Sciences Ltd.?
Currently, no hedge funds are holding shares in IN:SAILIFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SAI Life Sciences Ltd.
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is based in Hyderabad, India.
SAILIFE Stock 12 Month Forecast
Average Price Target
₹1,270.00
▲(25.71% Upside)
Technical Analysis
Jubilant Pharmova Limited
―
Laurus Labs Ltd.
―
Neuland Laboratories Ltd.
―
Piramal Pharma Limited
―
Syngene International Ltd.
―







